share_log

Goldman Sachs Maintains Neutral on GeneDx Hldgs, Lowers Price Target to $6

Benzinga ·  Nov 1, 2023 09:27

Goldman Sachs analyst Matthew Sykes maintains GeneDx Hldgs (NASDAQ:WGS) with a Neutral and lowers the price target from $7 to $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment